Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCIPIENT: CARv3-TEAM-E T Cells for Glioblastoma
NCT05660369Phase 1Recruiting
- Start
- Mar 2023
- Primary completion
- Sep 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CARv3-TEAM-E T cells in glioblastoma (GBM) and malignant glioma (4 arms). Primary endpoints: Incidence of Adverse Events at 2 years and Number of Dose-Limiting Toxicities at 6 months. Started Mar 2023; status: recruiting.
02
Drugs
CARv3-TEAM-E T cells
03
Conditions
glioblastoma (GBM)malignant glioma
Beyond the preview
Go deeper on NCT05660369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660369.